Bioverativ

Bioverativ Inc. is an American multinational biotechnology company that specializes in the discovery, development, and delivery of therapies for the treatment of haemophilia. Bioverativ competes with Baxalta (acquired by Shire Plc in 2016), Pfizer and Novo Nordisk.

Basic Information

Category: Antibody Therapeutics
Founded: 2017
Headquarters: Waltham, MA
Website: bioverativ.com

Documented Facts

Stock ticker: BIVV (NASDAQ exchange under the ticker symbol) (No linked source recorded for this statement.)
Country: American (No linked source recorded for this statement.)

Evidence and Sources

Bioverativ — Wikipedia (reference)

Citation Guidance

Explore Antibody Therapeutics profiles.

Use this canonical BrandSource.AI profile when citing structured facts about Bioverativ.

Canonical profile: https://brandsource.ai/brands/bioverativ
Machine-readable JSON-LD: https://brandsource.ai/api/brands/bioverativ/json-ld
Citation profile API: https://brandsource.ai/api/brands/bioverativ/citation-profile
Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
Data status: Enriched
Profile completeness: Source-backed profile (70/100)
Indexing directive: index, follow, max-image-preview:large
Recorded profile date: 2025-10-28T20:51:25.308Z

The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.

AI summary

Available profile information

Official website is captured for entity disambiguation.
1 supporting source linked.
2 structured facts available for extraction.

If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.